Elicio Therapeutics (Elicio Therapeutics) Net-Net Working Capital : $-0.76 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Elicio Therapeutics Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Elicio Therapeutics's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $-0.76.

The industry rank for Elicio Therapeutics's Net-Net Working Capital or its related term are showing as below:

ELTX's Price-to-Net-Net-Working-Capital is not ranked ^*
in the Biotechnology industry.
Industry Median: 4.19
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Elicio Therapeutics Net-Net Working Capital Historical Data

The historical data trend for Elicio Therapeutics's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicio Therapeutics Net-Net Working Capital Chart

Elicio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net-Net Working Capital

-4.53

-6.61

-7.65

-13.59

-0.30

Elicio Therapeutics Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net-Net Working Capital	Get a 7-Day Free Trial								-	0.91	-0.34	-0.30	-0.76

Competitive Comparison of Elicio Therapeutics's Net-Net Working Capital

For the Biotechnology subindustry, Elicio Therapeutics's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicio Therapeutics's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Elicio Therapeutics's Price-to-Net-Net-Working-Capital falls into.

Elicio Therapeutics Net-Net Working Capital Calculation

Elicio Therapeutics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

	Net-Net Working Capital		(A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(12.894	+	0.75 * 0	+	0.5 * 0	-	15.773
-	0	-	0)	/	9.60372
=	-0.30

Elicio Therapeutics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

	Net-Net Working Capital		(Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(11.853	+	0.75 * 0	+	0.5 * 0	-	19.61
-	0	-	0)	/	10.22
=	-0.76

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

Elicio Therapeutics (NAS:ELTX) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.

Elicio Therapeutics Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Elicio Therapeutics's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicio Therapeutics (Elicio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicio Therapeutics Inc (NAS:ELTX) » Definitions » Net-Net Working Capital

Comparable Companies

Traded in Other Exchanges

9HA:Germany

Address

One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA, USA, 02139

Website

https://www.elicio.com

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.

Executives

Yekaterina Chudnovsky	director	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Robert R Ruffolo	director
Peter Demuth	officer: Chief Scientific Officer	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Assaf Segal	director	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Annette Matthies	officer: Chief Business Officer	ONE KENDALL SQUARE, BUILDING 1400 WEST, SUITE 14303, CAMBRIDGE MA 02139
Robert Connelly	director, officer: CEO, President and Director	1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Julian Adams	director	C/O GAMIDA CELL, 673 BOYLSTON STREET, 4TH FLOOR, BOSTON MA 02116
Christopher Haqq	officer: See Remarks	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Carol Gail Ashe	director	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Brian Piekos	officer: Chief Financial Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Gregory S Curhan	officer: See Remarks	600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Itzhak Goldberg	officer: See Remarks	51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
John F. Neylan	officer: See Remarks	750 LEXINGTON AVENUE, NEW YORK NY 10022